In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT +2.55%), Johnson & Johnson (JNJ 0.81%), Sanofi (SNY 1.63%), Pfizer (PFE 2.18%), and Merck (MRK 2.99%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.